Abstract Session 10

Co-Chair(s)

• 

  Mala Shanmugam, MS, PhD (she/her/hers)

  Associate Professor
  Winship Cancer Institute, Emory University, Georgia
• 

  Enrique Ocio, MD, PhD

  Head of the Hematology Department
  Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain
  Santander, Cantabria, Spain

Presentations:

• 09:00 - 09:10 East Coast USA Time

  (OA-42) Clonotypic B Cells are Passengers During Malignant Transformation and not Drivers of Disease Progression in Plasma Cell (PC) Neoplasms
  

  Abstract Presenter: Bruno Paiva, PhD – Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
• 09:10 - 09:20 East Coast USA Time

  (OA-41) Clinical Validation of Revised Diagnostic Criteria for Light Chain MGUS and Risk of Progression to Malignancy
  

  Abstract Presenter: Lærke Sloth Andersen, MD (she/her/hers) – Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
• 09:20 - 09:30 East Coast USA Time

  (OA-44) Genomics Define Neoplastic Transformation in Multiple Myeloma Precursor Conditions
  

  Abstract Presenter: Francesco Maura, MD – Memorial Sloan Kettering
• 09:30 - 09:40 East Coast USA Time

  (OA-45) Cell-Free BCL2 exRNA, but not MYC or MIZ1, Identifies Smouldering Myeloma with a High Risk of Progression among Patients in the Myeloma Related Disease Registry (MRDR)
  

  Abstract Presenter: Daniel SL Wong, MBBS, FRACP, FRCPA – Alfred Health
• 09:40 - 09:50 East Coast USA Time

  (OA-43) Monoclonal Gammopathy of Indeterminate Potential (MGIP) as an Early and Premalignant Stage in the Evolution Toward Hematological Malignancies
  

  Abstract Presenter: Sungjae Kim, PhD – Cancer Program, Broad Institute